Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 29.42M 20.74M 18.12M 16.64M 15.52M 1.97B 29.92M 200M 77.66M 969M 77.88M 76.19M 3.34B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 29.19M 20.58M 17.98M 16.51M 15.4M 1.96B 29.69M 199M 77.05M 961M 77.27M 75.59M 3.31B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.03%
Yield 2024 *
-
Yield 2025 -
1 week-5.00%
1 month+578.57%
3 months-2.06%
6 months-26.98%
Current year-26.98%
1 week 0.09
Extreme 0.0929
0.1
1 month 0.02
Extreme 0.015
0.2
Current year 0.01
Extreme 0.014
0.2
1 year 0
Extreme 0.0033
0.2
3 years 0
Extreme 0.0005
0.25
5 years 0
Extreme 0.0005
0.25
10 years 0
Extreme 0.0005
0.25
Manager TitleAgeSince
Chief Executive Officer - 30/06/2019
Director of Finance/CFO - 16/08/2022
Chief Tech/Sci/R&D Officer - 16/09/2024
Director TitleAgeSince
Director/Board Member 62 -
Director/Board Member - 05/12/2017
Director/Board Member - 30/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-5.00% - - 19.92M
+1.86%+7.65%+55.77%+158.84% 1,063B
+3.57%+7.42%+69.09%+58.92% 611B
+3.99%+7.37%+36.87%+93.77% 444B
-1.20%-0.96%+26.12%+20.22% 324B
+4.94%+4.51%+39.76%+28.93% 285B
+2.42%+2.96%+30.77%+42.24% 283B
+2.47%+6.56%-24.26%-39.60% 219B
+3.55%+6.05%+26.04%+68.52% 195B
+4.21%+6.00%+17.72%+70.33% 156B
Average +2.11%+2.83%+30.88%+55.80% 397.85B
Weighted average by Cap. +1.85%+4.16%+41.60%+80.68%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.78 0.01 0.08 0.03 0.38 0.03 0.03 1.33
Net income -1.71M -1.2M -1.05M -966K -901K -115M -1.74M -11.63M -4.51M -56.2M -4.52M -4.42M -194M -3.53M -2.49M -2.18M -2M -1.86M -237M -3.59M -24.06M -9.32M -116M -9.35M -9.15M -401M
Net Debt -113K -79.4K -69.38K -63.71K -59.41K -7.56M -115K -767K -297K -3.71M -298K -292K -12.78M -231K -163K -142K -130K -122K -15.47M -234K -1.57M -609K -7.59M -610K -597K -26.15M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume
30/06/26 US$0.0950 -.--% 7,080
29/06/26 US$0.0950 +7.71% 2,920
26/06/26 US$0.0882 -11.80% 36,000

Annual profits - Rate of surprise